The purpose of these studies was to support the hypothesis that an undiscovered cannabinoid receptor exists in brain. 35 S]GTP␥S binding with an affinity appropriate for mediation by CB 1 receptors (K B Ϸ 0.5 nM). The remaining stimulation seemed to be inhibited with lower potency (IC 50 Ϸ 5 M) similar to that seen in CB 1 Ϫ/Ϫ membranes or in the absence of agonist. Further experiments determined that the effects of anandamide and WIN55212-2 were not additive, but that the effect of opioid, adenosine A1, and cannabinoid ligands were additive. Finally, assays of different central nervous system (CNS) regions demonstrated significant activity of cannabinoids in CB 1 Ϫ/Ϫ membranes from brain stem, cortex, hippocampus, diencephalon, midbrain, and spinal cord, but not basal ganglia or cerebellum. Moreover, some of these same CNS regions also showed significant binding of
S]GTP␥S binding was stimulated by anandamide and WIN55212-2 in brain membranes from both CB 1 ϩ/ϩ and CB 1 Ϫ/Ϫ mice. In contrast, a wide variety of other compounds that are known to activate CB 1 receptors, including CP55940, HU-210, and ⌬ 9 -tetrahydrocannabinol, failed to stimulate [ 35 
S]GTP␥S binding in CB 1
Ϫ/Ϫ membranes. In CB 1 Ϫ/Ϫ membranes, SR141716A affected both basal and anandamide-or WIN55212-2-induced stimulation of [ 35 S]GTP␥S binding only at concentrations greater than 1 M. In CB 1 ϩ/ϩ membranes, SR141716A inhibited only 84% of anandamide and 67% of WIN55212-2 stimulated [ 35 S]GTP␥S binding with an affinity appropriate for mediation by CB 1 receptors (K B Ϸ 0.5 nM). The remaining stimulation seemed to be inhibited with lower potency (IC 50 Ϸ 5 M) similar to that seen in CB 1 Ϫ/Ϫ membranes or in the absence of agonist. Further experiments determined that the effects of anandamide and WIN55212-2 were not additive, but that the effect of opioid, adenosine A1, and cannabinoid ligands were additive. Finally, assays of different central nervous system (CNS) regions demonstrated significant activity of cannabinoids in CB 1 Ϫ/Ϫ membranes from brain stem, cortex, hippocampus, diencephalon, midbrain, and spinal cord, but not basal ganglia or cerebellum. Moreover, some of these same CNS regions also showed significant binding of Ϫ/Ϫ mouse brain membranes via a common G protein-coupled receptor with a distinct CNS distribution, implying the existence of an unknown cannabinoid receptor subtype in brain.
Although the principal active constituent in marijuana, ⌬ 9 -tetrahydrocannabinol (THC), has been known for more than 35 years (Gaoni and Mechoulam, 1964) , the first cannabinoid receptor (CB 1 ) was cloned only 10 years ago (Matsuda et al., 1990) . The only other known cannabinoid receptor is CB 2 (Kaminski et al., 1992; Munro et al., 1993) , which is localized primarily on cells of the immune system. Both CB 1 and CB 2 are G protein-coupled receptors that seem to couple to inhibitory G i and/or G o proteins . CB 1 receptors are known to affect adenylyl cyclase (Howlett, 1984) , a variety of potassium (Deadwyler et al., 1995; Mackie et al., 1995; Mu et al., 1999) and calcium (Mackie and Hille, 1992; Mackie et al., 1995) currents, and the mitogen-activated protein kinase pathway (Bouaboula et al., 1995) . CB 1 receptors have been shown to activate at least six subtypes of G i and G o proteins, supporting the reports that they effect a wide variety of intracellular signaling systems (Prather et al., 2000) . CB 2 receptors also inhibit adenylyl cyclase and activate mitogen-activated protein kinase and Krox-24 pathways (Bouaboula et al., 1996) , but do not seem to effect ion currents directly (Felder et al., 1995) . In vivo, cannabinoids elicit a characteristic spectrum of behaviors in laboratory animals. These include catalepsy, analgesia, and decreases in spontaneous activity and body temperature (Adams and Martin, 1996) and a disruption of memory (Heyser et al., 1993) .
Receptor activation of G-proteins can be measured using agonist-stimulated binding of the nonhydrolyzable GTP analog, [ 35 S]guanosine-5Ј-O-(3-thiotriphosphate) ([ 35 S]GTP␥S) to membranes (Breivogel et al., 1997b) . Using this technique (Sim et al., 1998) or effects on adenylyl cyclase (Howlett, 1984) , it is possible to garner evidence for an unknown receptor before the development of selective, high-affinity radioligands.
There are two brain-derived chemicals that have been widely studied as candidate endogenous ligands for cannabinoid receptors. The first to be discovered was arachidonyl ethanolamide, or anandamide (Devane et al., 1992) . The second was also an arachidonic acid derivative, 2-arachidonyl glycerol (Mechoulam et al., 1995; Sugiura et al., 1995) . Neither compound has high affinity or potency at CB 1 or CB 2 , yet they seem to conform to many of the criteria for candidate neuromodulator compounds (Di Marzo et al., 1998) .
It has been proposed that the CB 1 receptor is the mediator of all of the CNS actions of cannabinoids. Evidence of this relationship is 3-fold: the structure-activity relationship for behavior and receptor affinity is highly correlated (Compton et al., 1993) ; the neuroanatomical localization of CB 1 receptors corresponds well with the CNS-mediated effects of cannabinoids ; and most of the CNS-mediated actions of cannabinoids seem to be reversible by the CB 1 -selective antagonist SR141716A (Compton et al., 1996) . However, a number of recent studies have found support for the concept of additional sites of action for cannabinoids (Jarai et al., 1999) . There is evidence that anandamide induces spinal antinociception via a different mechanism than THC or CP55940 (Welch and Eads, 1999; Houser et al., 2000) , and that the centrally-mediated in vivo actions of anandamide are not reversed by the CB 1 -selective antagonist, SR147161A (Adams et al., 1998) . Most recently, a study using transgenic C57BL/6 mice lacking the CB 1 receptor (CB 1 Ϫ/Ϫ ) revealed that anandamide still affected spontaneous activity, catalepsy, and analgesia, even though THC was inactive in these mice (Di Marzo et al., 2000) . In the same study, anandamide was found to stimulate [
35 S]GTP␥S binding to brain membranes from both CB 1 Ϫ/Ϫ and CB 1 ϩ/ϩ mice, but THC was active only in CB 1 ϩ/ϩ membranes. In the current study, WIN 55212-2 was also found to stimulate [ 35 S]GTP␥S binding in CB 1 Ϫ/Ϫ membranes. The goals of this study were to determine whether additional experiments confirmed or refuted the existence of a novel G protein-coupled cannabinoid receptor in brain. To accomplish this goal, the structure-activity profiles for various cannabinoids were determined, it was established whether anandamide and WIN55212-2 act at the same or separate sites, and it was determined whether there is a correlation between activity and specific binding of [ 3 H] ligands across membranes from various CNS regions and across different ligands.
Materials and Methods
Materials. CB 1 -receptor "knock-out" mutants were developed in C57BL/6 mice as described earlier . Mice were maintained on a 14-h/10-h light/dark cycle with free access to food and water. Spinal cords were taken whole and brains were taken whole or divided on ice into seven regions designated cerebellum, hippocampus, cortex, basal ganglia (striatum and globus pallidus), brain stem, midbrain, and diencephalon (thalamus and hypothalamus). Each preparation was homogenized with a Tissumizer (Tekmar, Cincinnati, OH) in cold membrane buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl 2 , 0.2 mM EGTA, 100 mM NaCl, pH 7.7) and centrifuged at 48,000g for 10 min at 4°C. Pellets were re-suspended in membrane buffer, then centrifuged again at 48,000g for 10 min at 4°C. Pellets from second centrifugation were homogenized in membrane buffer and stored at Ϫ80°C. Frozen membranes were thawed and diluted in membrane buffer, homogenized, and preincubated for 10 min at 30°C in 0.004 U/ml adenosine deaminase (240 U/mg protein; Sigma Chemical Co.) to remove endogenous adenosine, then assayed for protein content before addition to assay tubes. Assays were conducted at 30°C for 1 h in membrane buffer including 5 g of membrane protein with 0.1% (w/v) bovine serum albumin (BSA), 30 M GDP, and 0.10 nM [ 35 S]GTP␥S in a final volume of 0.5 ml. Nonspecific binding was determined in the absence of agonists and the presence of 30 M unlabeled GTP␥S. Reactions were terminated by rapid filtration under vacuum through Whatman GF/B glass fiber filters, followed by three washes with cold Tris-HCl buffer, pH 7.4. Bound radioactivity was determined by liquid scintillation spectrophotometry at 95% efficiency for 35 S after overnight extraction of the filters in 4 ml of BudgetSolve scintillation fluid (RPI Corp., Mount Prospect, IL).
[ 3 H]Ligand binding. The methods used for radioligand binding were as described previously (Griffin et al., 1998) . In initial experiments, binding was initiated by the addition of 25 g of membrane protein to siliconized tubes containing 10 nM tritiated radioligand (WIN 55212-2, SR141716A, or CP55940), and a sufficient volume of buffer to bring the total volume to 0.5 ml. In subsequent experiments, 100 g of cerebral cortex or cerebellar membranes and 8 to 85 nM [ 3 H]WIN55212-2 were used to determine dose dependence of specific radioligand binding. The addition of a 2-M concentration of the corresponding unlabeled ligand was used to assess nonspecific binding. The membranes were then incubated at 30°C for 60 min. The reaction was terminated by addition of ice-cold wash buffer (50 mM Tris HCl and 0.5% BSA, pH 7.4) followed by rapid filtration under vacuum through Whatman GF/C glass-fiber filters using a 12-well sampling manifold. The tubes were washed twice with 2 ml of ice-cold wash buffer and the filters rinsed twice with 4 ml of wash buffer. Filters were placed into 7-ml plastic scintillation vials and 5 ml of BudgetSolve scintillation fluid was added. is the concentration of agonists that produces half-maximal stimulation. Percent additivity ϭ S ab /(S a ϩ S b ) ϫ 100%, where S ab is stimulation produced by the combination of agonists, S a is stimulation produced by the first agonist alone (or combination of WIN55212-2 and anandamide), and S b is stimulation produced by second agonist alone. Significant stimulation by multiple concentrations of each ligand or in each brain region was determined by ANOVA followed by Dunnett's test at the p Ͻ 0.05 level to compare each concentration of ligand to basal binding. Significant specific binding of single concentrations of radioligand was determined by one-sample t tests (single concentrations of each ligand) or by ANOVA (for multiple concentrations) followed by Dunnett's test at the p Ͻ 0.05 level to compare with zero specific binding. All data presented are mean Ϯ S.E. of experiments performed in duplicate or triplicate in membranes from at least two different animals of each genotype, except where noted.
Results

Stimulation of [
35 S]GTP␥S Binding by Various Compounds. Results published previously by this laboratory (Di Marzo et al., 2000) have indicated that, although anandamide seems to be the endogenous ligand for cannabinoid receptors, it still exhibits activity for the stimulation of [ 35 S]GTP␥S binding in brain membranes from mice lacking the CB 1 receptor (CB 1 Ϫ/Ϫ ). Moreover, anandamide activity seemed to be equally potent in both CB 1 Ϫ/Ϫ and CB 1 ϩ/ϩ C57BL/6 mice, both for the stimulation of [ 35 S]GTP␥S binding and in whole-animal behavioral assays for cannabinoid activity. This activity proved to be insensitive to the CB 1 -and CB 2 -selective antagonists SR141716A and SR144528, at concentrations sufficient to block activity via each receptor. In contrast, ⌬ 9 -THC was active only in CB 1 ϩ/ϩ mice (Di Marzo et al., 2000) .
To follow-up the initial experiments, the present study uses agonist-stimulated [
35 S]GTP␥S binding to further characterize the activity and selectivity of this receptor in mouse brain. A total of 24 compounds were assayed for stimulation of [
35 S]GTP␥S binding in both CB 1 Ϫ/Ϫ and CB 1 ϩ/ϩ mouse whole-brain membranes. These compounds included an array of commonly used ligands for cannabinoid receptors and a number of analogs of both anandamide and WIN55212-2. This included: anandamide and 2-arachidonyl glycerol, ⌬ 9 -THC, ⌬ 8 -THC, cannabinol, cannabidiol, HU-210, HU-211, CP55940, CP55244, SR141716A, SR144528, the anandamide analogs 1Ј-methyl-anandamide (O-610), 2-methyl-anandamide (O-680), 2-dimethyl-anandamide (O-687) (Adams et al., 1995b) , 2-methylarachidonyl-(2Ј-fluoroethyl)amide (O-689) (Adams et al., 1995a) , WIN55212-2 (and several analogs: JWH-030, JWH-031, JWH-032, JWH-036, JWH-044, JWH-045, and JWH-073) (Wiley et al., 1998) . The only compounds that produced statistically significant dose-dependent stimulation of [
35 S]GTP␥S binding in CB 1 Ϫ/Ϫ membranes were anandamide and WIN55212-2 (Fig. 1) . All of the commonly used compounds (with the exception of SR144528, the inactive isomer HU-211, and the inactive cannabinol and cannabidiol) produced significant effects on [
35 S]GTP␥S binding in CB 1 ϩ/ϩ C57BL/6 whole brain membranes ( Fig. 1) , and others. However, the degree of stimulation was quite weak compared with anandamide and WIN55212-2, and the results for these ligands failed to achieve statistical significance. Among the analogs of ϩ/ϩ (IC 50 , 4.7 Ϯ 0.4 M; I max , Ϫ48 Ϯ 9 fmol/mg) and CB 1 Ϫ/Ϫ membranes (IC 50 , 5.7 Ϯ 2.1 M; I max , Ϫ50 Ϯ 9 fmol/mg).
In the present study, results for anandamide were similar to those previously published (see Table 2 ): E max of 41 fmol/mg (30 Ϯ 2% stimulation over basal binding) with an EC 50 value of 3.6 M in CB 1 Ϫ/Ϫ , whereas the corresponding values in CB 1 ϩ/ϩ membranes were 150 fmol/mg (91 Ϯ 4%) and 1.4 M ( (GDP) , and NaCl were varied (data not shown). All of the results were qualitatively the same as those previously observed using other ligands for other receptor systems (Breivogel et al., 1997b; Selley et al., 1998) or WIN55212-2 in wild-type rat brain membranes S]GTP␥S binding). However, the increase in binding over basal by agonists (and thus percent stimulation over basal binding) was greatest at the lowest concentration of protein (52% by WIN55212-2) and decreased with increasing protein (9.6% by WIN55212-2). Standard assay conditions in this study included 30 M GDP and 100 mM NaCl. Lowering either the concentration of GDP or NaCl increased the amount of binding obtained in either the absence (basal) or presence of agonist (30 M anandamide or 10 M WIN55212-2). However, because basal binding increased whereas net agonist-stimulated binding remained virtually the same as the concentrations of GDP and NaCl were decreased, percentage stimulation over basal binding decreased dramatically (from 62 to 5.2% by WIN55212-2). Although maximal percentage of stimulation was obtained at increased (100 M) GDP and 100 mM NaCl, net agonist-stimulated binding was greater, and thus experimental values were more consistent, at standard assay conditions (30 M GDP). These results indicated that this receptor behaves similarly to previously characterized G protein-coupled receptors with regard to the effects of time, amount of membranes, and concentrations of GDP and NaCl on [ Ϫ/Ϫ membranes (Di Marzo et al., 2000) . To further investigate the effects of SR141716A, concentration-effect curves were generated for SR141716A alone and in the presence of anandamide or WIN55212-2 in whole-brain membranes from both CB 1 ϩ/ϩ and CB 1 Ϫ/Ϫ mice (Table 2) . At concentrations greater than 1 M, SR141716A decreased basal [
35 S]GTP␥S binding in a concentration-dependant manner in CB 1 ϩ/ϩ by 48 Ϯ 9 fmol/mg and CB 1 Ϫ/Ϫ membranes by 50 Ϯ 9 fmol/mg, yielding IC 50 values of 4.7 Ϯ 0.4 M and 5.7 Ϯ 2.1 M, respectively (Fig. 2) . When combined with either 10 M anandamide or 10 M WIN55212-2, SR141716A concentration-effect curves fit better (F test, p Ͻ 0.05) to a two-site than to a one-site model in CB 1 ϩ/ϩ membranes: there was a high-potency site with IC 50 values from 2 to 24 nM and a low-potency site with IC 50 values between 3 and 13 M ( Ϫ/Ϫ membranes, it was important to determine whether these ligands were working through the same receptor. Experiments were conducted using 10 M anandamide, 10 M WIN55212-2, 10 M DAMGO , and 1 M PIA , each alone or in combination. Results indicated that combination of any two agonists except anandamide and WIN55212-2 were almost completely additive (between 89 and 104%) and were always higher than for either agonist alone for the stimulation of [
35 S]GTP␥S binding in both wild-type and CB 1 Ϫ/Ϫ membranes (Table 3) . Also, combinations of anandamide plus WIN55212-2 with either DAMGO or PIA were also additive compared with anandamide plus WIN55212-2 and either DAMGO or PIA alone (Table 3) . The values for combinations of anandamide and WIN55212-2 were higher than for anandamide alone and almost exactly equal to those obtained for WIN55212-2 alone in both CB 1 ϩ/ϩ and CB 1 Ϫ/Ϫ membranes. Although the previous experiments in this study were carried out in membranes prepared from whole mouse brain, a further goal of this study was to determine the brain regional distribution of the activity of the putative new cannabinoid receptor. Concentration-effect curves for the stimulation of [ 35 S]GTP␥S binding by both anandamide and WIN55212-2 were performed in eight regions of CB 1 Ϫ/Ϫ mouse CNS, including basal ganglia (caudate-putamen and globus pallidus), brain stem, cerebellum, cerebral cortex, diencephalon, hippocampus, midbrain, and spinal cord. Significant stimulation (ANOVA; p Ͻ 0.05) was found for both ligands in all regions except basal ganglia and cerebellum, where there was no significant activity of either ligand, and in spinal cord, significant stimulation was observed only with anandamide (Fig. 3A) . In CB 1 Ϫ/Ϫ animals, the regions exhibiting the greatest level of activity were cortex, midbrain, and hippocampus, followed by diencephalon and brain stem. Spinal cord contained the lowest level of activity among the regions that showed significant stimulation.
[ Ϫ/Ϫ cerebral cortex membranes between 10 and 100 g/0.5 ml (Fig. 4) . Percent specific binding reached a plateau from 50 to 100 g at a level of 20%. In subsequent experiments, 25 g of tissue was used to maximize specific binding while conserving tissue, which was of limited availability.
Radioligands, at concentrations of 10 nM, were then tested in each region prepared from both CB 1 ϩ/ϩ and CB 1 Ϫ/Ϫ C57BL/6 mice to determine whether there was significant specific binding. Statistically significant specific binding of each ligand was detected in each region of CB 1 ϩ/ϩ membranes (not shown). In contrast, total bound radioligand was very much reduced in CB 1 Ϫ/Ϫ compared with CB 1 ϩ/ϩ tissues, although significant specific binding (p Ͻ 0.05 one-sample t test) of [
H]WIN55212-2 and [
3 H]SR141716A were observed in some regions (Fig. 5) . The areas that demonstrated significant levels of bound [ 3 H]WIN55212-2 were the brain stem, cortex, and hippocampus (Fig. 3B) The first two rows were data obtained using various concentrations of either anandamide or WIN55212-2 alone. The next three rows are data obtained with 10 M anandamide or 10 M WIN55212-2 in the presence of various concentrations of SR141716A (see "SR ϩ 10 M WIN" and "SR ϩ 10 M anand." in Fig. 2 ). "High K B " and "Low IC 50 " refer to the two sites observed for inhibition of agonist-stimulated [
35 S]GTP␥S binding in CB 1 ϩ/ϩ membranes. "High K B " is the affinity of the high potency site at which SR141716A inhibited agonist stimulation in CB 1 ϩ/ϩ membranes and was calculated from the high-affinity IC 50 value as described under Materials and Methods. "Low IC 50 " is concentration of SR141716A that seem to inhibit half of the remaining stimulation by agonist in CB 1 ϩ/ϩ and was the only site observed in CB 1 Ϫ/Ϫ membranes. "% High potency" is the percentage of agonist-stimulated binding inhibited by SR141716A at the high K B value. The last two rows were obtained by subtracting the effects of SR141716A alone from the data obtained for agonists plus SR141716A for each experiment before nonlinear fitting of the data. "K B for ϪSR" is the affinity value exhibited by SR141716A, and "% Blocked ϪSR" is the percentage of agonist-stimulated binding inhibited by SR141716A (see "SR ϩ 10 M WIN ϪSR alone" and "SR ϩ 10 M anand. Ϫ SR alone" in Fig. 2 To further characterize the specific [ 3 H]WIN55212-2 binding observed in some regions of CB 1 Ϫ/Ϫ mouse brain membranes, it was important to determine whether the binding was concentration-dependent using higher concentrations of [ 3 H]WIN55212-2 used in the single-concentration analysis described above (Fig. 5) . Because analysis of the binding by high concentrations of these lipophilic radioligands was technically difficult, and use of such large amounts of radioligand is impractical, only two regions were selected. Cortex was chosen because it displayed some of the highest levels of both WIN55212-2-stimulated [ 35 Ϫ/Ϫ cerebellar membranes (ANOVA; p ϭ 0.06) (Fig. 5) .
Discussion
A previous study found that anandamide, but not THC, produced pharmacological effects in CB 1 Ϫ/Ϫ mice (Di Marzo et al., 2000) . In the present study, none of the classes of compounds represented by THC, CP55940, HU-210 or SR141716A were active, but anandamide and WIN55212-2 activated G proteins in brain membranes from CB 1 Ϫ/Ϫ mice. In contrast, none of the analogs of anandamide or WIN55212-2 were active. However, in an attempt to find ligands selective for the unknown receptor, analogs of WIN55212-2 were chosen that exhibited behavioral activity in mice but failed to displace [ 3 H]CP55940 binding in previous studies (see Table 1 ). In the present study, these analogs did not activate G proteins in CB 1 ϩ/ϩ or CB 1 Ϫ/Ϫ mouse membranes. Among the analogs active in CB 1 ϩ/ϩ membranes, all but JWH-073 exhibited lower potency than WIN55212-2 (see Table 1 ) and contained significant departures from the chemical structure of WIN55212-2. Moreover, each exhibited at least 33% lower efficacy than WIN55212-2, which represents stimulation by WIN55212-2 contributed by the putative new receptor.
That analogs of anandamide that differed structurally by one or two methyl groups did not activate G proteins in CB 1 Ϫ/Ϫ was somewhat unexpected. These compounds were more potent and exhibited equal or lower efficacy than anandamide in CB 1 ϩ/ϩ membranes. One interpretation is that O-610 and O-687 activated only CB 1 receptors and did so with efficacy similar to that of anandamide and that the additional efficacy observed for anandamide came from the activation of the unknown receptor, for which anandamide exhibited lower potency as well (yielding a higher EC 50 value). In contrast, O-680 exhibited similar efficacy but higher potency than anandamide in CB 1 ϩ/ϩ membranes. The lack of activity of O-680 in CB 1 Ϫ/Ϫ membranes may indicate higher intrinsic efficacy than anandamide at CB 1 . That each of these modifications to the structure of anandamide yielded compounds that were more potent at CB 1 and were no longer substrates for fatty acid amide hydrolase (Deutsch and Chin, 1993) argues that these alterations are significant and produce changes in three-dimensional structure. Perhaps the putative new receptor's binding pocket is more similar to that of fatty acid amide hydrolase than CB 1 . Alternatively, the lower potency of anandamide in CB 1 ϩ/ϩ membranes and the activity of anandamide in CB 1 Ϫ/Ϫ membranes might be attributed to degradation of anandamide. This seems unlikely, because pretreatment of the membranes with phenylmethylsulfonyl fluoride in the previous study (Di Marzo et al., 2000) had no effect on anandamide efficacy or potency.
Experiments designed to optimize the [ 35 S]GTP␥S binding assay for anandamide and WIN55212-2 in CB 1 Ϫ/Ϫ membranes found that optimal conditions were virtually the same as those for activation in CB 1 ϩ/ϩ membranes (Breivogel et al., 1997b) or for other receptor systems in brain (Sim et al., 35 S]GTP␥S binding. These manipulations were performed before nonlinear curve fitting of each of the resulting data sets. Curve fits are to one-or two-site models as described under Results and in Table 2 . Data are means Ϯ S.E. from three or four assays performed in triplicate.
1995; Selley et al., 1998) or cell (Breivogel et al., 1997a) membranes. These observations support the concept that the activities of anandamide and WIN55212-2 were due to activation of a G protein-coupled receptor.
In a previous study (Di Marzo et al., 2000) , neither SR141716A nor SR144528 affected activation of G proteins by anandamide in CB 1 Ϫ/Ϫ membranes at concentrations at least 50-fold greater than the K D values of the antagonists at CB 1 and CB 2 , respectively. In CB 1 ϩ/ϩ membranes in the present study, SR141716A inhibited CB 1 receptor-mediated activity with high potency, and remaining agonist stimulation was inhibited at the same concentrations that produced inhibition of basal [
35 S]GTP␥S binding. If the effect of SR141716A and the agonists at the low potency sites were mediated in a competitive manner, the concentrations of SR141716A necessary to produce inhibition in the presence of agonist would be higher than in the absence of agonist. Moreover, when the effect of SR141716A on basal binding was subtracted from the effect on agonist-stimulated binding, the inhibition of agonist-stimulated [
35 S]GTP␥S binding at the higher concentrations of SR141716A disappeared. Thus, it seems that the low-potency inhibition of [
35 S]GTP␥S binding by SR141716A in both CB 1 ϩ/ϩ and CB 1 Ϫ/Ϫ membranes was caused not by blockade of the site of anandamide and WIN55212-2 activity but by additive effects at different sites. These data demonstrate that the "inverse agonist" activity of SR14716A was mediated by neither CB 1 nor the putative new cannabinoid receptor.
Another finding was that the amount of activity of the unknown receptor seemed to be equivalent in CB 1 ϩ/ϩ and CB 1 Ϫ/Ϫ membranes. Stimulation produced by anandamide and WIN55212-2 in CB 1 Ϫ/Ϫ membranes, 41 fmol/mg and 64 fmol/mg, respectively, was virtually the same as that refractory to SR141716A in CB 1 ϩ/ϩ membranes, 33 and 60 fmol/ mg, respectively (calculated from Table 2 ). This indicated that deletion of the CB 1 gene did not effect the expression or activity of the putative new receptor, an important consideration because the genes for these two receptors may be related. Additivity experiments implied that anandamide and WIN55212-2 acted at the same site in CB 1 Ϫ/Ϫ membranes, and that anandamide is a partial agonist at this site relative to WIN55212-2. Moreover, it seemed that neither nor A1 activity was altered by deletion of CB 1 .
These data show that anandamide and WIN55212-2 activity was localized to discreet CNS areas of CB 1 Ϫ/Ϫ mice, which coincided to some degree with areas exhibiting specific binding of (Breivogel et al., 1997b) , radioligand binding (Breivogel et al., 1997b) , and CB 1 mRNA in situ hybridization (Mailleux and Vanderhaeghen, 1992) Houser et al., 2000) . That WIN55212-2 has previously been shown to be the most efficacious cannabinoid agonist (Sim et al., 1996; Breivogel and Childers, 2000) , may be explained by the existence of this second G protein-coupled target for WIN55212-2. It was shown previously that WIN55212-2 was as efficacious as levonantradol in rat cerebellum but was 20 to 30% more efficacious in hippocampus and hypothalamus membranes . This agrees with the data in the present study that showed no activity of WIN55212-2 in CB 1 Ϫ/Ϫ cerebellum, but highly significant activity in hippocampus and diencephalon (which included hypothalamus). That anandamide is not more efficacious than other cannabinoid ligands despite its activity at a second target is explained by its lower intrinsic efficacy at both CB 1 and this new receptor.
These data strongly support the existence of a previously uncharacterized, G protein-coupled cannabinoid receptor in brain, and cast light into its kinetic and ligand recognition properties, as well as its CNS distribution. It seems to be related to CB 1 and CB 2 , because two chemically unrelated compounds that produce cannabinoid pharmacological effects activate this receptor. It is interesting to note that compounds derived from cannabis, from which "cannabinoid" nomenclature is derived, do not activate this receptor. This receptor may provide a new target for therapeutics, because it seems to have very different structural requirements from CB 1 and may have different physiological effects. However, although these data provide strong evidence for a novel receptor, proof must involve cloning and expression of a novel gene.
